Case series of BRAF-mutated advanced melanoma treated with encorafenib plus binimetinib combination therapy.

Abstract

The efficacy of encorafenib plus binimetinib (E+B) combination therapy for BRAF-mutated advanced melanoma as second-line therapy and beyond is still unknown. In this report, we investigated 22 cases of BRAF-mutated advanced melanoma treated with E+B combination therapy. The objective response rate (ORR) for the total cohort was 68.4%. Notably, the ORR for the second-line and beyond cohort was 73.3%, suggesting that the therapeutic effect of E+B combination therapy is comparable with that of first-line targeted therapy. In contrast, overall survival and progress-free survival in our present cohort was worse than that in a previous clinical trial. Notably, although the incidence rate of severe adverse events was higher than that in a previous report, our present study suggested that E+B combination therapy is a well-tolerated antimelanoma regimen. Our present study suggested that the efficacy and safety profile of E+B combination therapy as a second-line therapy and beyond is comparable with that of first-line targeted therapy.